Trial · NCT03611621
Results by group45
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 45
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Evaluation of Graft Survival in Subjects Who Have Undergone Kidney Transplantation After Imlifidase Administration. | Imlifidase | 91 | 95% Confidence Interval 75 to 97 | percentage | |
| Evaluation of Long-term Clinical Outcomes of Transplanted Subjects Treated With Imlifidase in Terms of Patient Survival. | Imlifidase | 92 | 95% Confidence Interval 77 to 97 | percentage | |
| Evaluation of Long-term Clinical Outcomes of Transplanted Subjects Treated With Imlifidase in Terms of Kidney Function (Estimated Glomerular Filtration Rate (eGFR)). | Imlifidase | 50.74 | Standard Deviation 19.38 | mL/min/1.73m2 | |
| Evaluation of Long-term Clinical Outcomes of Transplanted Subjects Treated With Imlifidase in Terms of Kidney Function (Plasma (P)-Creatinine). | Imlifidase | 141.3 | Standard Deviation 69.9 | μmol/L | |
| Evaluation of Long-term Clinical Outcomes of Transplanted Subjects Treated With Imlifidase in Terms of Kidney Function (Proteinuria). | Imlifidase | Positive | 14 | Participants | |
| Evaluation of Long-term Clinical Outcomes of Transplanted Subjects Treated With Imlifidase in Terms of Kidney Function (Proteinuria). | Imlifidase | Negative | 13 | Participants | |
| Evaluation of Long-term Clinical Outcomes of Transplanted Subjects Treated With Imlifidase in Terms of Kidney Function (Proteinuria). | Imlifidase | Not done | 3 | Participants | |
| Evaluation of Long-term Clinical Outcomes of Transplanted Subjects Treated With Imlifidase in Terms of Number of Graft Rejection Episodes. | Imlifidase | 0 suspected acute rejection episodes | 23 | Participants | |
| Evaluation of Long-term Clinical Outcomes of Transplanted Subjects Treated With Imlifidase in Terms of Number of Graft Rejection Episodes. | Imlifidase | 1 suspected acute rejection episode | 7 | Participants | |
| Evaluation of Long-term Clinical Outcomes of Transplanted Subjects Treated With Imlifidase in Terms of Treatment of Graft Rejection Episodes. | Imlifidase | 2 | Participants | ||
| Evaluation of Long-term Clinical Outcomes of Transplanted Subjects Treated With Imlifidase in Terms of Comorbidities. | Imlifidase | urinary tract infection | 9 | participants with comorbidity | |
| Evaluation of Long-term Clinical Outcomes of Transplanted Subjects Treated With Imlifidase in Terms of Comorbidities. | Imlifidase | nasopharyngitis | 3 | participants with comorbidity | |
| Evaluation of Long-term Clinical Outcomes of Transplanted Subjects Treated With Imlifidase in Terms of Comorbidities. | Imlifidase | pyelonephritis | 3 | participants with comorbidity | |
| Evaluation of Long-term Clinical Outcomes of Transplanted Subjects Treated With Imlifidase in Terms of Comorbidities. | Imlifidase | upper respiratory infection | 4 | participants with comorbidity | |
| Evaluation of Long-term Clinical Outcomes of Transplanted Subjects Treated With Imlifidase in Terms of Comorbidities. | Imlifidase | Covid-19 infection | 4 | participants with comorbidity | |
| Evaluation of Long-term Clinical Outcomes of Transplanted Subjects Treated With Imlifidase in Terms of Comorbidities. | Imlifidase | urosepsis | 2 | participants with comorbidity | |
| Evaluation of Long-term Clinical Outcomes of Transplanted Subjects Treated With Imlifidase in Terms of Comorbidities. | Imlifidase | sepsis | 2 | participants with comorbidity | |
| Evaluation of Long-term Clinical Outcomes of Transplanted Subjects Treated With Imlifidase in Terms of Comorbidities. | Imlifidase | pneumonia | 2 | participants with comorbidity | |
| Evaluation of Long-term Clinical Outcomes of Transplanted Subjects Treated With Imlifidase in Terms of Comorbidities. | Imlifidase | diabetes mellitus | 4 | participants with comorbidity | |
| Evaluation of Long-term Clinical Outcomes of Transplanted Subjects Treated With Imlifidase in Terms of Treatments of Comorbidities. | Imlifidase | Tacrolimus | 29 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03611621/results